|
|
 |
|
Viewing report
|
|
|
|
European Biomarker Analysis Market
Frost & Sullivan, Sep 2009, Pages: 107
This research service gives a detailed analysis of the biomarker analysis market in Europe from 2005-2015.
This Frost & Sullivan research service titled European Biomarker Analysis Market provides revenue forecasts, competitive analysis and market trends for proteomics biomarkers, genomics biomarkers, metabolomic biomarkers, imaging biomarkers, and companion diagnostics. In this research, Frost & Sullivan's expert analysts thoroughly examine biomarker applications in genomics, proteomics and metabolomics. The countries covered in this research service are Germany, France, Italy, Spain, The United Kingdom, Benelux, and Scandinavia.
Market Overview
Biomarkers to Aid Reduction of Drug Development Time and Costs, Spurring Growth in the European Biomarker Analysis Market
The -omics revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years with excellent growth prospects. Biomarkers have a multitude of applications such as early disease detection, identifying potential drug targets, predicting patient response to medication, and accelerating clinical trials. Along with its role in making personalised medicine a reality, this technology enjoys priority in terms of funding and investments. The promise of biomarkers to shorten drug development time and decrease costs in the long-term is likely to act in tandem to spur growth in the biomarker analysis market. “Currently, biomarker testing is sporadic and mainly restricted to large biotech and pharma companies,” says the analyst of this research. “Although the regulators are gradually mandating biomarker testing for the widespread adoption by all tiers of biotech and pharma companies, pharma companies also need to find a means of converging drug development workflow with biomarker development workflow to facilitate cost-effective and accessible biomarker testing.”
Cancer biomarkers and cardiovascular biomarkers have been found to have the greatest growth among the disease areas. Central nervous system (CNS) biomarkers are also not far behind, and have been found to have excellent growth potential mainly due to the tremendous thrust in Alzheimer’s biomarker research. The biomarker analysis market is set to grow exponentially for most of the next seven years except in the short-term, where growth rates have been predicted with caution and conservativeness to factor in any reduction in growth due to the on-going financial slowdown.
Biomarker Development Costs Should be Shared by Benefactors
There seems to be a lag between the discovery of biomarkers in the laboratory and its commercialisation due to major roadblocks in biomarker validation and assay development. While biomarker testing in itself is inexpensive, the process of biomarker discovery and assay development is costly. Currently, target validation, high-throughput compound screening, and lead discovery are processes that take place as a separate workflow, whereas biomarker discovery, assay development and testing that come much later, are a parallel workflow. The union between these two workflows is a necessary but not a sufficient condition for biomarker testing to go mainstream. Since the costs involved with managing two parallel workflows for a single drug development programme are high, only the pharmaceutical leviathans with the needed financial backing can successfully implement this model. “The integration of the workflows is happening, albeit at a slow pace,” notes the analyst. “A workable solution is expected to be reached by the pharmaceutical industry in the next five or more years to come.”
In order to get a quicker return-on-investment (ROI) all the benefactors of biomarker discovery and development should share costs as the resulting biomarker will be beneficial to all those involved. This can help to lower the biomarker development costs significantly and make it more accessible to the pharmaceutical and biotechnology industry. “Although the task of uniting the entire industry towards this cause is a formidable one, at present this seems to be the only solution to the challenge of making biomarker testing reach every drug discovery lab,” concludes the analyst. “The long-term benefits of such an undertaking will aid in justifying the efforts that are involved in making it happen.”
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
Personalized Medicine - Scientific and Commercial Aspects
Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Costs
European Cell Based Assays Markets
Biomarkers, Tests and Trends for Drug R&D
Overview of the European Drug Discovery Market
European Cancer IVD Market
Biomarkers - Advanced Technologies and Global Market (2009-2014)
Commercial Opportunities from Biomarkers: Transforming drug discovery, clinical development and molecular diagnostics
Global Cancer Biomarkers Market (2010 - 2015)
|
|
|
|
